Medulloblastoma (MB) is the most frequent infratentorial malignant brain tumor in children.
In contrast, primitive neuroectodermal tumor (PNET) is defined as a supratentorial malignant …

Recent efforts at stratifying medulloblastomas based on their molecular features have
revolutionized our understanding of this morbidity. Collective efforts by multiple independent …

Medulloblastoma (MB) is the most common CNS embryonal tumor. While the overall cure
rate is around 70%, patients with high‐risk disease continue to have poor outcome and …

Childhood medulloblastomas (MB) are heterogeneous and are divided into four molecular
subgroups. The provisional non-wingless-activated (WNT)/non-sonic hedgehog-activated …

The diagnosis of medulloblastoma likely encompasses several distinct entities, with recent
evidence for the existence of at least four unique molecular subgroups that exhibit distinct …

Medulloblastoma in infants and young children is a major challenge to treat because
craniospinal irradiation (CSI), a cornerstone of therapy for older children, is …

Aims Biomarker‐driven therapies have not been developed for infant medulloblastoma
(iMB). We sought to robustly sub‐classify iMB, and proffer strategies for personalized, risk …

Comprehensive molecular characterization of infant medulloblastoma has uncovered the
high degree of heterogeneity of this disease. Recent results from the SJYC07 study …

Abstract Medulloblastoma (MB) represents approximately 4% of adult brain tumours, and as
such is a poorly studied disease. Although many adult MB are treated using paediatric MB …

Medulloblastoma is a malignant embryonal brain tumor with highly variable outcome. In
order to study the biology of this tumor and to perform preclinical treatment studies, a lot of …